ASK1-IN-1 |
| Catalog No.GC19041 |
ASK1-IN-1 est un puissant inhibiteur compétitif de l'ATP disponible par voie orale et sélectif de la kinase 1 régulatrice du signal d'apoptose (ASK1) avec une IC50 de 2,87 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1262041-49-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ASK1-IN-1 is an apoptosis signal regulating kinase 1 (ASK1) inhibitor extracted from patent WO2016025474A1, Compound 4.
ASK1-IN-1 dose-dependently decreases pulmonary arterial pressure and right ventricular (RV) hypertrophy in an in vivo model of pulmonary hypertension (PH). ASKl inhibition reduces hallmarks of pulmonary vascular disease including and not limited to reduce pulmonary vascular resistance (PVR), improve pulmonary pressure, decreased pulmonary vascular remodeling, improved vascular function, decrease maladaptive RV hypertrophy, and improve RV function. Inhibition of ASKl signaling may slow, prevent, and/or reverse pathological changes associated with PH. Plasma levels of B-type natriuretic peptide (BNP) are reduced by both doses of ASK1-IN-1: 0.1+0.05 for 0.1% and 0.1±0.1 ng/mL for 0.2%. Su/Hx rats treated with 0.1 % or 0.2% ASK1-IN-1 has a decreased number of completely muscularized arterioles (35.6% and 32.6%, respectively)[1].
References:
[1]. Grant Raymond BUDAS, et al. Methods of treating pulmonary hypertension. WO2016025474A1.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *